Severe Influenza
Conditions
Keywords
severe Influenza
Brief summary
This is a multicenter, randomized, open Label, add-on study.
Detailed description
This is an add-on study of efficacy and safety of intravenous injection of Xiyanping injection in pediatric subjects with severe Influenza-Like Symptoms. The purpose to determine the efficacy and safety of Oseltamivir Phosphate combined with or without Xiyanping injection in the treatment of severe Influenza-Like Symptoms. The study will enroll 72 Pediatric severe Influenza-Like Symptoms volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive Oseltamivir Phosphate and Xiyanping injection for severe Influenza; volunteers from the second group will receive Oseltamivir Phosphate for severe Influenza. Xiyanping injection will be administration as intravenous injection of 0.4mL/kg/day once daily for 7-10 days concomitantly with Oseltamivir Phosphate for severe Influenza-Like Symptoms.
Interventions
Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
DRUGXiyanping injection+Oseltamivir Phosphate
Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
Sponsors
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Beijing Luhe Hospital
Qingdao Municipal Hospital
Cangzhou People's Hospital
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 6 Years
Healthy volunteers
No
Inclusion criteria
* Age between 3 and 6 years old; * Clinical diagnosis of Severe Influenza with hospital treatment needed; * Patients did not accept oseltamivir phosphate treatment or symptoms persisted for more than 3 days treatment; （1)Fever ≥ 39°C (tympanic temperature) for at least 3 days with Severe cough,sputum, blood stasis, or chest pain; （2）Combined pneumonia; * The rapid viral antigen test of throat swab and nose swab results were positive; * Guardians understood and assigned the informed consent;
Exclusion criteria
* Participants allergenic to XiYanPing injection, Andrographolide or Oseltamivir Phosphate; * Creatinine clearance \<80ml/min or received continuous renal replacement therapy (CRRT) test; * Need extracorporeal membrane oxygenation (ECMO) at baseline; * Glasgow Coma Rating Scale (GCS) score ≤ 9 points when dyspnea, altered consciousness, severe vomiting, or coma appeared at baseline; * Crisis influenza Symptoms, such as respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction and other serious clinical conditions requiring monitoring; * Use of systemic steroids or other immunosuppressants; * Participants with the following underlying diseases, including: heart disease (such as New York Heart Function Classification II-IV) or clinically significant arrhythmia (such as QTc ≥ 480ms), malignant tumor or other malignant diseases, autoimmune diseases; liver and kidney diseases ( ALT and AST ≥ 1.5 × ULN; Cr and BUN \> 1.2 × ULN), blood diseases, nervous system diseases, immune system diseases and endocrine diseases, consciousness, speech, behavioral abnormalities caused by encephalitis / encephalopathy or limb paralysis, severe malnutrition, etc. * Participants used Influenza virus vaccine within 3 months; * Participants with drug dependence or with mental disorders within 1 year; * Participants participated in other clinical research in the last 30 days; * Any condition which would make the subject, in the opinion of the investigator or designee, not suitable for the study for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Alleviation of Influenza Signs and Symptoms | Up to Day 12 | Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the signs and symptoms are alleviation or recovery. |
| Duration of Fever | Up to Day 12 | Length of time taken by participants to return to afebrile state |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Cessation of Viral Shedding by RT-PCR | Up to Day 12 | — |
| Relief time of individual symptom such as:expectoration, cough | Up to Day 12 | — |
| Signs and Symptoms Score from baseline | Up to Day 12 | (1) recovery: symptom score reduction rate ≥ 95%; (2) markedly effective: symptom score reduction rate ≥ 70%; (3) progress: symptom score reduction rate ≥ 30%; (4) invalid: Symptom score reduction rate \<30%. |
| Imaging improvement rate: number of people with normal or baseline imaging | Up to Day 12 | — |
| Disease efficacy criteria | Up to Day 12 | (1) Healing: The body temperature is normal within 48 hours of treatment, the symptoms disappeared without repetition. (2) markedly effective: the body temperature is normal within 48 hours of treatment, and the symptom score is reduced by more than 2/3. (3) Effective: The body temperature is normal within 72 hours of treatment, and the remaining symptom scores are reduced by 2/3-1/3. (4) Invalid: The condition did not improve or worsened after 72 hours of treatment. |
| Usage of antibiotic,hormone and incidence of critical cases | Up to Day 12 | — |
Countries
China
Contacts
Primary ContactXilian Zhang
Outcome results
None listed